Trials / Completed
CompletedNCT00640809
Comparison of Small Bowel Lesions Associated With Celecoxib Versus Ibuprofen Plus Omeprazole
Double-Blind, Placebo-Controlled, Randomized Two-Week Study, Comparing Small Bowel Lesions Associated With Celecoxib (200 mg BID) vs. Ibuprofen (800 mg TID) Plus Omeprazole (20 mg QD)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 408 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the small bowel lesion pattern associated with celecoxib alone versus ibuprofen plus omeprazole
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Celecoxib | 200 mg oral capsule twice daily for 2 weeks |
| OTHER | Placebo | Matched placebo for 2 weeks |
| DRUG | Ibuprofen plus Omeprazole | ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks |
Timeline
- Start date
- 2003-10-01
- Completion
- 2004-04-01
- First posted
- 2008-03-21
- Last updated
- 2021-02-02
Locations
12 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00640809. Inclusion in this directory is not an endorsement.